Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dostarlimab in dMMR/MSI-H Endometrial Cancer (China RUBY)
NCT07108270Phase 2Recruiting
- Sponsor
- GSK
- Start
- Nov 2025
- Primary completion
- Mar 2030
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of dostarlimab in endometrial cancer (EC), sponsored by GSK. Started Nov 2025; status: recruiting.
02
Drugs
dostarlimab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT07108270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07108270.